

DAFTAR PUSTAKA

- Acuner-Ozbabacan, E. S., Engin, B. H., Guven-Maiorov, E., Kuzu, G., Muratcioglu, S., Baspinar, A., Nussinov, R. (2014). The structural network of Interleukin-10 and its implications in inflammation and cancer. *BMC Genomics*, 15 Suppl 4(Suppl 4), S2. doi:10.1186/1471-2164-15-S4-S2
- Asadullah, K., Sterry, W., & Volk, H. D. (2003). Interleukin-10 therapy--review of a new approach. *Pharmacological Reviews*, 55(2), 241-69. doi:10.1124/pr.55.2.4
- Bhairavabhotla, R. K., Verma, V., Tongaonkar, H., Shastri, S., & Dinshaw, K. (2007). Role of IL-10 in immune suppression in cervical cancer, 44(October), pp. 350-356.
- Beisserts, S., Hosoi, J., Grabbe, S., Asahina, A., Granstein, R.D. (1995). IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. *J Immunol*, 154(3), pp. 1280-6.
- Berger, S., Siegert, A., Denkert, C., Köbel, M. & Hauptmann, S. (2001). Interleukin-10 in serous ovarian carcinoma cell lines. *Cancer Immunology, Immunotherapy*, 50(6), pp. 328-333.
- Boulland, M-L., Meignin, V., Leroy-Viard, K., Copie-Bergman, C., Brière, J., Touitou, R., Kanavaros, P. & Gaulard, P. (1998). Human Interleukin-10 Expression in T/Natural Killer-Cell Lymphomas. *The American Journal of Pathology*, 153(4), pp. 1229-1237.
- Brooker R. (2009). *Genetics: Analysis and Principles*. Yale: McGrawHill.
- Brown, J., Frumovitz, M. (2014). Mucinous tumors of the ovary: current thoughts on diagnosis and management. *Curr Oncol Rep*, 16(6), pp. 389.

- Cacev, T., Radosevic, S., Krizanac, S. & Kapitanovic, S. (2008). Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. *Carcinogenesis*, 29(8), pp. 1572-1580.
- Coward, J.I.G., Middleton, K., Murphy, F. (2015). New perspectives on targeted therapy in ovarian cancer. *International Journal of Women's Health*, 7, pp. 189-203.
- Dennis, K.L., Blatner, N.R., Gounari, F. & Khazaie, K. (2013). Current status of interleukin-10 and regulatory T-cells in cancer. *Current Opinion in Oncology*, 25(6), pp. 637-645.
- Dummer, W., Bastian, B.C., Ernst, N., Schänzle, C., Schwaaf, A. & Bröcker, E-B. (1996). Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions. *International Journal of Cancer Int. J. Cancer*, 66(5), pp. 607-610.
- Ebrahimi, B., Tucker, S.L., Li, D., Abbruzzese, J.L., Kurzrock, R. (2004). Cytokines in pancreatic carcinoma. *Cancer*, 101(12), pp. 2727-36.
- Fujieda, S., Lee, K., Sunaga, H., Tsuzuki, H., Ikawa, H., Fan, G-K., Imanaka, M., Takenaka, H. & Saito, H. (1999). Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. *Cancer*, 85(7), pp. 1439-1445.
- Garcia-Hernandez, M.L., Hernandez-Pando, R., Gariglio, P. & Berumen, J. (2002). Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. *Immunology*, 105(2), pp. 231-243.
- Geng, L., Huang, D., Liu, J., Qian, Y., Deng, J., Li, D., Hu, Z., Zhang, J., Jiang, G. & Zheng, S. (2008). B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. *Journal of Cancer Research and Clinical Oncology J Cancer Res Clin Oncol*, 134(9), pp. 1021-1027.

- Gotlieb, W.H., Abrams, J.S., Watson, J.M., Velu, T.J., Berek, J.S., Martínez-Maza, O. (1992). Presence of interleukin-10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. *Cytokine*, 4(5), pp. 385-390.
- Hamidullah, Changkija, B. and Konwar, R. (2011). Role of interleukin-10 in breast cancer. *Breast Cancer Res Treat*, 133(1), pp.11-21.
- Hamzavi, M., Tadbir, A.A., Rezvani, G., Ashraf, M.J., Fattahi, M.J., Khademi, B., Sardari, Y. & Jeirudi, N. (2013). Tissue expression, serum and salivary level of IL-10 in patients with head and neck squamous cell carcinoma. *Asian Pacific Journal of Cancer Prevention*, vol. 14(3), pp. 1681-1685.
- Hart, W.R. (2005). Mucinous Tumors of the Ovary: A Review. , 78(1), pp.4-25.
- Hauptmann, S., Dietel, M. (2001). Serous tumors of low malignant potential of the ovary-molecular pathology: part 2. *Virchows Arch*, 438(6), pp. 539-551.
- Itakura, E., Huang, R-R., Wen, D-R., Paul, E., Wunsch, P.H. & Cochran, A.J. (2011). IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence," *Mod Pathol Modern Pathology*, vol. 24, no. 6, pp. 801-809.
- Krüger-Krasagakes, S., Krasagakis, K., Garbe, C., Schmitt, E., Hüls, C., Blankenstein, T. & Diamantstein, T. (1994). Expression of interleukin 10 in human melanoma. *Br J Cancer British Journal of Cancer*, 70(6), pp. 1182-1185.
- Kumar, V., Abbas, A., Aster, J. and Robbins, S. (2013). Robbins basic pathology. Philadelphia, PA: Elsevier/Saunders.
- Li, O. (2013). The paradox of IL-10-mediated modulation in cervical cancer (Review). *biom rep*.

- Liu, J. (2011). Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer, *World Journal of Gastroenterology WJG*, 17(10), p. 1362.
- Mocellin, S. (2005). Interleukin-10 and the immune response against cancer: a counterpoint. *Journal of Leukocyte Biology*, 78(5), pp.1043-1051.
- Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol*, 19, pp. 683-765.
- Mustea, A., Könsgen, D., Braicu, E. I., Pirvulescu, C., Sun, P., Sofroni, D., Sehouli, J. (2006). Expression of IL-10 in Patients with Ovarian Carcinoma, 1718, 1715-1718.
- Nelson, B. H. (2008). The impact of T-cell immunity on ovarian cancer outcomes. *Immunological Reviews*, 222, 101-16. doi:10.1111/j.1600-065X.2008.00614.x
- O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., & Hawrylowicz, C. (2008). Strategies for use of IL-10 or its antagonists in human disease. *Immunological Reviews*, 223(1), 114-131.
- Oemiati, R., Rahajeng, E., Kristanto, A. Y. (2011). Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhinya di Indonesia. *Buletin Penelitian Kesehatan*, 39(4), pp.190-204.
- Pisa, P., Halapi, E., Pisa, E.K., Gerdin, E., Hising, C., Bucht, A., Gerdin, B. & Kiessling, R. (1992). Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies, *Proceedings of the National Academy of Sciences*, 89(16), pp. 7708-7712.
- Pratidina, R.W.G. (2012). Perbedaan Ekspresi Interleukin 10 antara Kistadenoma dengan Kistadenokarsinoma Ovarium Tipe Serosum
- Radji, M. (2011). Molecular Targeted Therapy and teknologi Penghantaran Obat.

Ramkumar, H.L., Shen, D.F., Tuo, J., Braziel, R.M., Coupland, S.E., Smith, J.R. & Chan, C-C. (2012). IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas, *Graefes Arch Clin Exp Ophthalmol Graefe's Archive for Clinical and Experimental Ophthalmology*, 250(10), pp. 1541-1548.

Richardsen, E., Uglehus, R., Johnsen, S. & Busund, L-T. (2012). Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer, *BMC Research Notes BMC Res Notes*, 5(1), p. 110.

Robbins, S., Kumar, V. and Cotran, R. (2010). Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders/Elsevier.

Rubenstein, J.L., Wong, V.S., Kadoch, C., Gao, H-X., Barajas, R., Chen, L., Josephson, S.A., Scott, B., Douglas, V., Maiti, M., Kaplan, L.D., Treseler, P.A., Cha, S., Hwang, J.H., Cinque, P., Cyster, J.G. & Lowell, C. (2013). CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. *Blood*, 121(23), pp. 4740-4748.

Salazar-Onfray, F. (1999). Interleukin-10: a cytokine used by tumors to escape immunosurveillance. *Med Oncol*, 16(2), pp. 86-94.

Soria, J-C., Moon, C., Kemp, B.L., Liu, D.D., Feng, L., Tang, X., Chang, Y-S., Mao, L., Khuri, F.R. (2003). Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. *Clinical Cancer Research*, 9, pp. 1785-91.

Spits, H., de Waal Malefyt, R. (1992). Functional characterization of human IL-10, *Int Arch Allergy Immunol*, 99(1), pp: 8-15.

Stanilov, N., Miteva, L., Jovchev, J., Deliyiski, T., Stanilova, S. (2010) Role of IL-12P40 and IL-10 in progression of colorectal cancer. *Khirurgiia (Sofia)*, (4-5) pp. 26-29.

- Syrjänen, S., Naud, P., Sarian, L., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Eržen, M., Hammes, L.S., Costa, S. & Syrjänen, K. (2009), Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort, *Virchows Archiv*, 455(6), pp. 505-515.
- Taylor, H.C. (1929). Malignant and semi-malignant tumors of the ovary. *Surg Gynecol Oncol*, 86, pp. 34-37.
- Tjindarbumi, D., Mangunkusumo, R. (2002). Cancer in Indonesia, Present and Future. *Jpn J Clin Oncol*, 32(Supplement 1), pp. s17-21.
- Vergote, I., Tropé, C., Amant, F., Kristensen G., Ehlen, T., Johnson, N., Verheijen, R., van Der Burg, M., Lacave, A., Panici P., Kenter, G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G., Pecorelli, S., and Reed, N. (2010). Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. *New England Journal of Medicine*. 363(10), pp. 943-953.
- Vicari, A.P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M.P., O'Garra, A., Trinchieri, G., Caux, C. (2002). Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody. *J. Exp. Med*, 196(4), pp.541-549.
- Wang, Y. A. N., Liu, X. H., Li, Y. U. E. H., & Li, O. U. (2013). The paradox of IL - 10 - mediated modulation in cervical cancer (Review), (16), pp. 347-351. doi:10.3892/br.2013.69
- Wei, Y.G. (2011). Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis, *World Journal of Gastroenterology WJG*, 17(34), p. 3941.
- Wu H.C., Chang D.K., Huang C.T. (2006). Targeted Therapy for Cancer. *J. Cancer Mol*, 2(2), pp. 57-66.

- Yang, L., Carbone, D.P. (2004). Tumor-host immune interactions and dendritic cell dysfunction. *Adv Cancer Res*, 92, pp.13-27.
- Yue, F.Y., Dummer, R., Geertsens, R., Hofbauer, G., Laine, E., Manolio, S., Burg, G. (1997). Interleukin-10 is a growth factor for human melanoma cells and down regulates HLA class-I, HLA class-II and ICAM-1 molecules. *International Journal of Cancer*, 71(4), pp. 630-637.
- Zeni, E., Mazzetti, L., Miotto, D., Lo Cascio, N., Maestrelli, P., Querzoli, P., Boschetto, P. (2007). Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. *The European Respiratory Journal*, 30(4), pp.627-32. doi:10.1183/09031936.00129306
- Zhou, J., Ye, F., Chen, H., Lv, W., & Gan, N. (2007). The Expression of Interleukin-10 in Patients with Primary Ovarian Epithelial Carcinoma and in Ovarian Carcinoma Cell Lines. *Journal of International Medical Research*, 35(3), pp.290-300. doi:10.1177/14732300070350030